The oral antiviral market size valued for $35.213 billion in 2021 and is estimated to reach $43.394 billion by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.
Antiviral drugs are a class of medicines particularly used for the treatment of viral infections. Specific antiviral drugs are used for treating specific type of viruses. Oral antiviral agents are medications that are taken by mouth to treat viral infections. In addition, antiviral drugs, unlike the most antibiotics, do not destroy their target pathogens; rather inhibit their development. Further, these drugs work by interfering with various stages of the viral life cycle, such as replication or assembly, reduce the severity and duration of symptoms, as well as reduce the spread of the virus to others. Moreover, many oral antiviral drugs are approved and available for treating viral infections such as baloxavir marboxil & zanamivir for influenza, ledipasvir-sofosbuvir for hepatitis and darunavir & lamivudine for human immunodeficiency virus (HIV).
One of the driving factors in the oral antiviral market is an increase of viral infections such as influenza, human immunodeficiency virus (HIV) and hepatitis. For instance, according to the report of the Centers for Disease Control and Prevention (CDC) 2022, 9 million cases of influenza were reported, with 4 million medical visits and 10,000 hospitalizations. In addition, rising hepatitis and herpes cases across the globe is anticipated to drive the growth of market. Furthermore, an increase in the number of pipeline medications for treating viral infections that is anticipated to receive regulatory approval in the upcoming years; thus, driving the growth of market.
Furthermore, rising initiatives by non-government & government organizations to increase awareness about viral diseases and available oral treatment among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, a rise in adoption of advanced technologies to diagnose viral diseases and awareness about the importance of early diagnosis of viral infections such as hepatitis and human immunodeficiency virus (HIV) is anticipated to boost market growth. Furthermore, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global oral antiviral market, which is expected to drive the growth of the market.
However, factors such as the high cost of oral antivirals might restrain the growth of oral antiviral market. In addition, availability of vaccines for viral diseases such as influenza, hepatitis, human papillomavirus (HPV) and herpes is expected to hamper the growth of market. Moreover, rising demand of novel therapeutics for treating viral infections and a rise in regulatory approvals for antiviral drugs is expected to offer lucrative opportunities to key players of market.
The global oral antiviral market is segmented into indication, drug class, distribution channel, and region. On the basis of indication, the market is categorized into hepatitis, human immunodeficiency virus (HIV), influenza and others. On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global oral antiviral market include AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Key Report Benefits
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antiviral market analysis from 2021 to 2031 to identify the prevailing oral antiviral market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the oral antiviral market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global oral antiviral market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
- Hepatitis
- Human Immunodeficiency Virus (HIV)
- Influenza
- Others
By Drug class
- Protease inhibitors
- Reverse transcriptase inhibitors
- Others
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- F. Hoffman-La Roche Ltd
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Amneal Pharmaceuticals LLC
- Viatris Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
Table of Contents
Executive Summary
According to the report titled, “Oral Antiviral Market," the oral antiviral market size was valued at $35,213.48 million in 2021 and is projected to reach $43,394.00 million by 2031, growing at a CAGR of 2.1% from 2022 to 2031.Oral antiviral drugs are medications that are taken by mouth to treat viral infections. They work by either stopping the virus from replicating or preventing the virus from entering healthy cells.
Key factors driving the growth of the oral antiviral drugs market are rise in prevalence of viral infections such as hepatitis, influenza, and increase in research activities for development of novel therapeutics. For instance, according to report of World Health Organization (WHO) 2022, stated that, seasonal epidemic outbreaks of influenza affect up to 1 billion people each year, causing 3 - 5 million severe cases which need hospitalization. Thus, rise in prevalence of influenza cases has led to need for effective treatment options such as increase in the use of oral antiviral drugs, thereby driving the growth of market. Further, prevalence of hepatitis in children results in demand of effective oral antiviral drugs and drives the market growth.
In addition, prevalence of hepatitis of unknown etiology in children under the age of 10 years is observed which drives the growth of market. For instance, according to report of World Health Organization (WHO) 2022, stated that, 74 cases of unknow etiology had been identified in the UK, thereby driving the growth of market. Moreover, rise in research activities for the development of new and more effective oral antiviral drugs is driving market growth. Biotech and pharmaceutical companies are investing heavily in research and development to identify new targets for antiviral drugs, and to develop drugs that are more potent, have fewer side effects, and can be taken orally.
Further, the increasing awareness and education about viral infections among healthcare providers and the general public has led to an increase in early diagnosis and treatment, further driving the market for treatments for the condition. In addition, rise in funding for development of effective antivirals is expected to contribute to growth of market. For instance, in March 2022, Novo Nordisk Foundation and the Bill & Melinda Gates Foundation announced funding of $90 million toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. Thus, rise in such funding results in research activities and boost the growth of market.
In addition, rise in number of key players offering novel drugs and rise in regulatory approvals is anticipated to drive the growth of market. For instance, key players such as Gilead Sciences, Inc., GlaxoSmithKline, Novartis AG, and Merck & Co., offer novel antiviral medications, thus a rise in the number of key players is expected to drive the market growth.
The market also offers growth opportunities to the key players in the market. Many developing regions such India and Brazil offer lucrative opportunities to key players of oral antiviral drugs market owing to high population base, increase in demand of novel formulations for treating viral infections and increase in healthcare spending. In addition, government sponsored research studies regarding viral infections in various countries and medical tourism fuels the growth of oral antiviral drugs market.
The global oral antiviral market is segmented into indication, drug class, distribution channel, and region. On the basis of indication, the market is categorized into hepatitis, human immunodeficiency virus (HIV), influenza and others. On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. The players in the market have been actively engaged in the adoption various strategies such product approval, funding and agreement to remain competitive and gain advantage over the competitors in the market.
Key Market Insights
- On the basis of indication, the HIV segment dominated the market in terms of revenue in 2021.
- On the basis of drug class, reverse transcriptase inhibitors segment dominated the market in terms of revenue in 2021.
- On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- F. Hoffman-La Roche Ltd
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Amneal Pharmaceuticals LLC
- Viatris Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 385 |
| Published | February 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 35.21 Billion |
| Forecasted Market Value ( USD | $ 43.39 Billion |
| Compound Annual Growth Rate | 2.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
